816 related articles for article (PubMed ID: 23790596)
21. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
Hankey GJ
Thromb Haemost; 2014 May; 111(5):808-16. PubMed ID: 24285341
[TBL] [Abstract][Full Text] [Related]
22. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
Escobar C; Barrios V; Jimenez D
Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
[TBL] [Abstract][Full Text] [Related]
23. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
24. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis.
Baker RI; Coughlin PB; Gallus AS; Harper PL; Salem HH; Wood EM;
Med J Aust; 2004 Nov; 181(9):492-7. PubMed ID: 15516194
[TBL] [Abstract][Full Text] [Related]
25. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.
Lip GY; Bongiorni MG; Dobreanu D; Lewalter T; Hastrup Svendsen J; Blomström-Lundqvist C;
Europace; 2013 Oct; 15(10):1526-32. PubMed ID: 24072770
[TBL] [Abstract][Full Text] [Related]
26. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
Becattini C; Vedovati MC; Agnelli G
Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
[TBL] [Abstract][Full Text] [Related]
27. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
[TBL] [Abstract][Full Text] [Related]
28. NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?
Merinopoulos I; Venables P; Chalmers I; Vassiliou V
Recent Adv Cardiovasc Drug Discov; 2015; 10(1):60-4. PubMed ID: 26365270
[TBL] [Abstract][Full Text] [Related]
29. Direct oral anticoagulants: new drugs and new concepts.
Levy JH; Spyropoulos AC; Samama CM; Douketis J
JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
[TBL] [Abstract][Full Text] [Related]
30. [The application of thrombin generation tests to warfarin anticoagulation monitoring].
Chen HY; Ding QL; Zhang LW; Xu GQ; Dai J; Wang XF; Xi XD; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):168-70. PubMed ID: 18788615
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.
Jones M; McEwan P; Morgan CL; Peters JR; Goodfellow J; Currie CJ
Heart; 2005 Apr; 91(4):472-7. PubMed ID: 15772203
[TBL] [Abstract][Full Text] [Related]
32. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.
Leissinger CA; Blatt PM; Hoots WK; Ewenstein B
Am J Hematol; 2008 Feb; 83(2):137-43. PubMed ID: 17729241
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption.
Nutescu EA; Bathija S; Sharp LK; Gerber BS; Schumock GT; Fitzgibbon ML
Pharmacotherapy; 2011 Dec; 31(12):1161-74. PubMed ID: 22122179
[TBL] [Abstract][Full Text] [Related]
34. Perioperative use of prothrombin complex concentrates.
Colomina MJ; Díez Lobo A; Garutti I; Gómez-Luque A; Llau JV; Pita E
Minerva Anestesiol; 2012 Mar; 78(3):358-68. PubMed ID: 22357373
[TBL] [Abstract][Full Text] [Related]
35. What to do when warfarin therapy goes too far.
Prasad S; Wootten MR; Kulinski N; Chapman SA
J Fam Pract; 2009 Jul; 58(7):346-52. PubMed ID: 19607771
[TBL] [Abstract][Full Text] [Related]
36. [ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].
Colonna P; Abrignani MG; Colivicchi F; Verdecchia P; Alunni G; Bongo AS; Ceravolo R; Oliva F; Rakar S; Riccio C; Scherillo M; Valle R; Bovenzi F;
G Ital Cardiol (Rome); 2013 Apr; 14(4):295-322. PubMed ID: 23567775
[TBL] [Abstract][Full Text] [Related]
37. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
[TBL] [Abstract][Full Text] [Related]
38. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
[TBL] [Abstract][Full Text] [Related]
39. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Acharjee S; Cannon CP
Crit Pathw Cardiol; 2011 Jun; 10(2):84-6. PubMed ID: 21988948
[TBL] [Abstract][Full Text] [Related]
40. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
Vanassche T; Hirsh J; Eikelboom JW; Ginsberg JS
Thromb Haemost; 2014 Nov; 112(5):918-23. PubMed ID: 25187203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
